There were some people who were giving it only a 50-50 chance [Pfizer] would win. We thought it was a big probability that they'd win. It's not a surprise the stock is moving up. A lot of value investors were on the sidelines, because they just don't buy things that have a huge risk in front of them.
These drugs all work in one mechanism. If someone came out with a different type of erectile dysfunction drug there might be potential to expand the ED market, but these three drugs essentially do the same thing.
They both could be key products.
We think it might make sense for them to try and focus on what they do well, which is Phase III testing and marketing,
We've seen [generic challengers'] success rate go down dramatically over last year. The drug companies are getting more experienced at defending these challenges.
You just can't grow the top line. I view Pfizer as a duck. They're floating and it looks easy, but they're paddling like crazy underneath.
Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.
Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.